AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Kuros Biosciences Ltd.

Earnings Release Feb 17, 2012

916_rns_2012-02-17_761676f3-d6c2-48de-b799-243b84a0766c.html

Earnings Release

Open in Viewer

Opens in native device viewer

News Details

Corporate | 17 February 2012 07:00

Cytos Biotechnology Ltd announces full year 2011 financial results

Cytos Biotechnology AG / Key word(s): Final Results

17.02.2012 / 07:00


Schlieren (Zurich), Switzerland, February 17, 2012 – Cytos Biotechnology Ltd (SIX:CYTN) today presented its full year 2011 financial results.

The complete press release as well as the Annual Report 2011 can be downloaded on Cytos Biotechnology’s website ( www.cytos.com ).

For further information please contact:

Cytos Biotechnology Ltd

Harry Welten

Chief Financial Officer

Tel.: +41 44 733 46 46

e-Mail: [email protected]

Website: www.cytos.com

About Cytos Biotechnology Ltd

Cytos Biotechnology Ltd is a Swiss public biotechnology company that specializes in the development and commercialization of a new class of biopharmaceutical products – the Immunodrugs(TM). Immunodrugs(TM) are intended for use in the treatment and prevention of common chronic diseases, which afflict millions of people worldwide. Immunodrugs(TM) are designed to instruct the patient’s immune system to produce desired therapeutic antibody or T cell responses that modulate chronic disease processes. The Immunodrug(TM) candidates are developed both in-house and together with Novartis, Pfizer and Pfizer Animal Health. Founded in 1995 as a spinoff from the Swiss Federal Institute of Technology (ETH) in Zurich, the Company is located in Schlieren (Zurich). Cytos Biotechnology Ltd is listed on the main segment at the SIX Swiss Exchange (SIX:’CYTN’).

End of Corporate News


17.02.2012 News transmitted by EquityStory AG.

The issuer is responsible for the contents of the release.

EquityStory publishes regulatory releases, media releases on the capital market and press releases.

The EquityStory Group distributes authentic and real-time financial news for over 1’300 listed companies.

The Swiss news archive can be found at http://www.equitystory.ch/nachrichten


Language: English
Company: Cytos Biotechnology AG
Wagistr. 25
8952 Schlieren
Switzerland
Phone: +41 44 733 4747
Fax: +41 44 733 4740
E-mail: [email protected]
Internet: www.cytos.com
ISIN: CH0011025217, CH0029060735
Swiss Security Number:
Listed: Freiverkehr in Berlin, München, Stuttgart; Open Market in Frankfurt; SIX
End of News EquityStory AG News-Service
- - -
157148  17.02.2012

Talk to a Data Expert

Have a question? We'll get back to you promptly.